I agree that this site is using cookies. You can find further informations here.
X
Ujjani, C.
84  results:
Search for persons X
?
1

Ibrutinib and Venetoclax in Relapsed and Refractory Follicu..:

Ujjani, C. ; Wang, H. ; Broome, C....
Hematological Oncology.  41 (2023)  S2 - p. 381-382 , 2023
Link: https://doi.org/10.1002/..
 
?
2

Response‐adapted mosunetuzumab for untreated follicular and..:

Lynch, R. C. ; Poh, C. ; Shadman, M....
Hematological Oncology.  41 (2023)  S2 - p. 577-578 , 2023
Link: https://doi.org/10.1002/..
 
?
3

S207: EFFICACY AND SAFETY OF A THIRD GENERATION CD20 CART (..:

Shadman, M. ; Yeung, C. ; Redman, M....
HemaSphere.  6 (2022)  - p. 108-109 , 2022
Link: https://doi.org/10.1097/..
 
?
4

P671: TREATMENT SEQUENCES AND OUTCOMES OF PATIENTS WITH CLL..:

Mato, A. R. ; Manzoor, B. S. ; Coombs, C. C....
HemaSphere.  6 (2022)  - p. 569-570 , 2022
Link: https://doi.org/10.1097/..
 
?
5

S147: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVE..:

Mato, A. R. ; Pagel, J. M. ; Coombs, C. C....
HemaSphere.  6 (2022)  - p. 48-49 , 2022
Link: https://doi.org/10.1097/..
 
?
6

Pilot Prognostic Model for Survival in r/r DLBCL Patients R..:

Eastman, B. ; Hippe, D.S. ; Smith, S.C....
International Journal of Radiation Oncology*Biology*Physics.  111 (2021)  3 - p. e299-e300 , 2021
Link: https://doi.org/10.1016/..
 
?
7

A WINDOW STUDY OF IXAZOMIB IN UNTREATED B‐NHL:

Graf, S.A. ; Lynch, R.C. ; Ujjani, C....
Hematological Oncology.  37 (2019)  S2 - p. 570-571 , 2019
Link: https://doi.org/10.1002/..
 
?
8

PHASE IB/II STUDY OF IBRUTINIB AND VENETOCLAX IN RELAPSED A..:

Ujjani, C. ; Wang, H. ; Leslie, L...
Hematological Oncology.  37 (2019)  S2 - p. 569-570 , 2019
Link: https://doi.org/10.1002/..
 
?
9

Major clinical response to nivolumab in relapsed/refractory..:

Yared, J A ; Hardy, N ; Singh, Z...
Bone Marrow Transplantation.  51 (2016)  6 - p. 850-852 , 2016
Link: https://doi.org/10.1038/..
 
?
10

PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED MANTLE ..:

Cheah, C. Y. ; Shah, N. N. ; Jurczak, W....
Hematological Oncology.  41 (2023)  S2 - p. 153-156 , 2023
Link: https://doi.org/10.1002/..
 
?
11

HIGH EFFICACY AND FAVORABLE SAFETY OF 3RD GENERATION CD20 C..:

Shadman, M. ; Yeung, C. ; Redman, M....
Hematological Oncology.  41 (2023)  S2 - p. 87-88 , 2023
Link: https://doi.org/10.1002/..
 
?
12

A PILOT TRIAL OF ADRIAMYCIN, PEMBROLIZUMAB, VINBLASTINE AND..:

Lynch, R.C. ; Smith, S.D. ; Shadman, M....
Hematological Oncology.  37 (2019)  S2 - p. 572-573 , 2019
Link: https://doi.org/10.1002/..
 
?
13

Treatment Discontinuation Patterns for Patients With Chroni..:

Shadman, M ; Manzoor, BS ; Sail, K...
https://discovery.ucl.ac.uk/id/eprint/10171712/1/Treatment%20Discontinuation%20CLL.pdf.  , 2023
Link: https://discovery.ucl.ac..
 
?
14

P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REV..:

Eyre, T. A ; Wang, M. L ; Shah, N. N...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430028/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
15

Targeted Therapy for Relapsed/Refractory Follicular Lymphom..:

Raychaudhuri R ; Ujjani C
https://www.dovepress.com/targeted-therapy-for-relapsedrefractory-follicular-lymphoma-focus-on-c-peer-reviewed-fulltext-article-OTT.  , 2022
Link: https://doaj.org/article..
 
1-15